retatrutide clinical development Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and What Is Retatrutide And How

Unlike prescription GLP-1 receptor agonists, which commonly cause significant nausea, vomiting, and gastrointestinal distress due to delayed gastric emptying, probiotic-related symptoms are typically less severe and mechanistically different

When appetite is low, focus on protein shakes, smoothies, and nutrient-dense small meals

Bariatric surgery has also been shown to reduce risk of major adverse cardiovascular outcomes and diabetes

Evidence from Pregnancy Studies and Extrapolation to Lactation GLP-1 use during pregnancy is generally not recommended due to limited fetal safety data, though no definitive teratogenic signal has emerged

These are most prominent when starting the medication and during dose escalation, and typically improve as the body adjusts

Sanchez-Andres, Willy J